Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis backs off...

    Novartis backs off from 2016 date for testing Google autofocus lens

    Written by supriya kashyap kashyap Published On 2016-11-21T10:38:27+05:30  |  Updated On 21 Nov 2016 10:38 AM IST

    Zurich : Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."


    "It is too early to say when exactly human clinical trials for these lenses will begin," a spokeswoman for the Basel-based drug maker said in an email.


    "This is a very technically complex process and both sides are learning as we go along. We will provide updates at the appropriate time," she said.


    Novartis Chief Executive Joe Jimenez said last year his company's Alcon eye care unit was on track to begin testing in 2016.


    In 2014, Jimenez said he hoped the lens would be on the market in about five years.


    Novartis and Google joined forces two years ago to develop two kinds of "smart" contact lenses: An autofocusing lens for people with presbyopia, or far-sightedness, and another for measuring blood glucose levels in diabetes patients.


    The lenses are now being developed with Alphabet Inc.'s life sciences unit Verily, which was carved out from Google in 2015.


    Measuring blood sugar via the eye could allow diabetics to stop having to prick their fingers, while an autofocus contact lens would help people whose ability to focus is impaired when their eyes age.


    It is unclear when testing for the diabetes lens will start.


    Since the partnership with Google was launched in 2014, Alcon's sales have slid and its leadership team has been replaced.


    New division head Mike Ball has been tasked with halting the revenue decline in advance of a possible sale of the unit.


    But Novartis said that did not bar investment in innovative projects such as the lens effort with Google.


    "Advancing innovation such as the smart lens technology, is a key part of Alcon's growth strategy," the spokeswoman said.


    "The 'smart lens' technology has the potential to transform eye care and further enhance our pipeline in the contact lens and intraocular lens space."

    Alcon eye careautofocus lensblood glucosediabetesdiabetes patienttsGoogle autofocus lensIntraocular LensJoe JimenezNovartis
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok